about
Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre studySystemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national surveyCardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinionIdentification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approachUse of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis.Autoantibodies directed against the amino-terminal domain I of human calpastatin (ACAST-DI Ab) in connective tissue diseases. High levels of ACAST-DI Ab are associated with vasculitis in lupus.Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany).Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion.Diagnosis of peripheral psoriatic arthritis: recommendations for clinical practice based on data from the literature and experts opinion.Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion.Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion.The sternocostoclavicular joint: normal and abnormal features.Epistatic interaction between BANK1 and BLK in rheumatoid arthritis: results from a large trans-ethnic meta-analysis.Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.A new tool for rheumatology: large-scale analysis of gene expression.Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritisRole and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors.Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a studyEarly and long-standing rheumatoid arthritis: distinct molecular signatures identified by gene-expression profiling in synoviaSmoking and inflammatory diseases.Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.Diagnostic and prognostic usefulness of antibodies to citrullinated peptides.Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis.Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review.Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.[Diagnosis of early arthritis].Septic arthritis of the hip caused by Yersinia enterocolitica: a case report.Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort.Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
P50
Q24815550-5C829EBF-130C-4529-A9A9-FE3CD747B597Q24816756-917E6AA0-EF88-439B-962E-BCA7C08C809BQ28217906-662B9BCD-C541-438E-B147-D0AE1D065A45Q28542901-9B769001-EAD3-4A8E-B7B7-8A15C0D646F4Q30807010-BD0E0D37-1C46-4D9E-AD15-3250E59930BAQ30836381-616FBD66-37A5-4CFA-AC4E-8DE3FF34A46DQ30860243-5880EE21-9592-4D5F-AA64-191A72FBBC2FQ33405505-A54879B2-147E-48B9-886D-007616A6DF01Q33417857-533CE6C1-9DC9-4492-B26E-0EBA3F499054Q33449134-70157C93-4377-4AE5-8F30-C541A1257BFBQ33452403-8CDF1843-60CB-4E09-A021-24F4D315A096Q33578743-62628282-5BB0-40BD-9A42-5F38B4EB3A3CQ33623141-618A1D28-A95F-49D7-AB97-B7E23FDA04B6Q34654581-5D6E36A1-B524-4CFE-9F91-85882B75A772Q34706667-8A321C39-35C7-45D3-A6BB-61F083614469Q34945123-9E1D459E-2512-4D73-A373-C862204C4191Q35023731-DE8E562A-EB8A-4358-A0A7-78CB0F1BDF05Q35209870-CA0BDC83-5A7E-42C3-8F1E-E2801EFC19C7Q35605604-206EDD44-072F-4821-B059-08ECA27EA89DQ36083502-DB7C8D8D-A405-4887-A927-47CB35284CB3Q36105879-D73ED29E-0F37-487B-B33F-19FCCF22AD38Q36454542-F020963F-5589-42BF-AA70-76AB8439A6B1Q36477380-7ED59D55-193C-420C-9CD1-A88BE1B8EF29Q36694682-957EC516-C24E-45B2-9FAB-6DFD17F6C404Q36859283-4CA344D1-D065-47C6-AA1F-864E26509859Q36859291-3702A1C8-F0B1-4DF7-99E3-6011204E5920Q37270882-7F6F9F7B-D863-4BD1-BB46-818CBEF4116EQ37270899-48073FD1-B03E-4E29-A389-46732CBDBB60Q37333118-0D5C63BC-8026-4AC8-90E9-093443225B3DQ37453985-5E7DD66C-874F-40A1-AF6B-6769F149CB75Q37518539-13860979-90E1-4D60-955E-305704745C59Q37753155-5D888CE1-D678-4A57-9973-42315B6B03EAQ37833377-5E39F0CE-8A8C-4F96-9BF9-FEFF0132D0A8Q37858789-59BD5289-D92C-4C58-A8A2-60E3548562CBQ37890664-242B3F44-1F89-4944-83C0-DDB52BF128DFQ40047193-CB796994-5BD8-45AF-BA9F-8FF52FD072BFQ40483633-A01DB69F-888A-4396-8C84-F796FD572949Q40567181-59EBD237-163B-41B1-A754-27AFFED80690Q40991763-8E1AFB38-A90E-4DAD-B035-536F832611EFQ41086414-F1499CC3-3B13-48C8-AE05-F5D088737DBC
P50
name
Xavier Le Loët
@ast
Xavier Le Loët
@en
Xavier Le Loët
@nl
type
label
Xavier Le Loët
@ast
Xavier Le Loët
@en
Xavier Le Loët
@nl
prefLabel
Xavier Le Loët
@ast
Xavier Le Loët
@en
Xavier Le Loët
@nl